Evaluation of a Differentiated Point-of-care Active Case Finding & Management Model to Eliminate Mother-to-Child Transmission of HIV in Malawi (PAC-Man)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Purpose: To conduct a hybrid effectiveness-implementation stepped-wedge trial to:
- Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of infants who receive timely EID testing.
- Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of pregnant and breastfeeding women living with HIV who receive guideline-adherent viral load testing.
- Compare implementation outcomes between the PAC-Man model and SOC.
Participants: The total study sample size is 2,426, including 2,304 mother-infant pair (MIP) survey participants, 48 high-risk pregnant/breastfeeding women living with HIV for in-depth interviews (from high-risk MIPs who participated in a survey); 10 PMTCT policy makers and Ministry of Health (MOH)/ President's Emergency Plan for AIDS Relief (PEPFAR) implementing partner senior managers for key informant interviews; and about 48-64 professional and lay health providers for focus group discussions and implementation actor surveys.
To rigorously evaluate the PAC-Man model, investigators will use a hybrid (type 3) effectiveness-implementation incomplete stepped-wedge trial design. The hybrid incomplete stepped-wedge design is a rigorous quasi-experimental design that allows for incremental "rollout" of the PAC-Man model and serial measurement of both health outcomes (for infants and mothers in Objectives 1 and 2, respectively), as well as implementation outcomes (Objective 3). The incomplete stepped-wedge design is more efficient than a complete design, minimizes costs, and reduces participant burden, without sacrificing statistical precision. Using this design, sequential crossover from control (i.e., the SOC) to intervention (i.e., SOC plus the PAC-Man model) takes place at each 'step' using cluster randomization until all clusters (defined as a group of "sites," or health facilities plus the surrounding communities in its catchment area) receive the intervention. The 12 sites included in our study will be divided into 4 clusters of 3 sites each.
Full description
PAC-Man Model:
PAC-Man represents an integrated differentiated services delivery (DSD) model for mothers and infants that brings the following three evidence-based practices into the community for elimination of mother to child transmission (EMTCT): 1) pediatric active case finding using novel point-of-care (POC) early infant diagnosis (EID) technology; 2) same-day antiretroviral therapy (ART) initiation for infants newly diagnosed with HIV infection; and 3) maternal viral load (mVL) testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs in which the mother living with HIV did not initiate ART, started ART late during pregnancy or breastfeeding, dropped off treatment following ART initiation, was unsuppressed on ART, was identified with HIV infection for the first-time during the post-partum period, and/or did not return with her infant for EID testing. Because these evidence-based practices are already recommended by the Ministry of Health and will be functioning at the site and not the individual level, delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA™ in community settings.
PAC-Man Implementation Approaches:
The overall implementation strategy being evaluated in this study is the creation of mobile care teams to deploy m-PIMA™ and provide EMTCT services in the community. Complementing this overarching strategy will be two sub-strategies used to enhance PAC-Man adoption: 1) task shifting of active case finding, EID and mVL testing, ART initiation, and back-to-care services to community health workers (CHWs), community nurses, and HIV diagnostic assistants; and 2) changing service sites to convenient locations in the community to overcome barriers to EID and mVL delivery. These strategies are intended to work in concert with the above evidence-based practices to integrate PAC-Man into the EMTCT program.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
The criteria for Enumerated MIP Cohort is as follows:
Inclusion Criteria:
- Enrolled in the national EMTCT program at a study site in the 12 months preceding a survey.
Exclusion Criteria:
- None.
The criteria for Enumerated MIP Field Survey is as follows:
Inclusion Criteria:
- Age 16 years or older.
- Enrolled in the national EMTCT program at a study site in the 12 months preceding a survey.
Exclusion Criteria:
- Documented transferred out from a site prior to the field survey.
- Participated previously in the field survey.
- Decline informed consent.
The criteria for In-Depth Interviews is as follows:
Inclusion criteria:
- Age 16 years or older.
- Met high-risk criteria for PAC-Man model.
- Participated in a field survey.
Exclusion criteria:
- Decline informed consent.
The criteria for Focus Group Discussions is as follows:
Inclusion criteria:
- Age 18 years or older.
- MOH or implementing partner professional or lay health worker at a study site (such as nurses, community health workers, health surveillance assistants, and HIV diagnostic assistants)
- Generally familiar with the PAC-Man model and/or EMTCT/ EID service delivery at their site.
Exclusion criteria:
- Decline informed consent.
The criteria for Key Informant Interviews is as follows:
Inclusion criteria:
- Age 18 years or older.
- HIV/ EMTCT policy maker OR MOH/ PEPFAR implementing partner senior manager.
- Generally familiar with HIV and/or EMTCT/ EID service delivery.
Exclusion criteria:
- Decline informed consent.
The criteria for Implementation Actor Questionnaires is as follows:
Inclusion criteria:
- Age 18 years or older.
- Professional or lay health provider at a study site.
- Generally familiar with HIV and/or EMTCT/ EID service delivery at their site.
- Participated in a focus group discussion.
Exclusion criteria:
- Decline informed consent.
Trial design
Primary purpose
Allocation
Interventional model
Masking
2,426 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Michael Herce, MD, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal